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Sophia Osawe 4 and Kenneth L. Rosenthal 3* for the InFANT Study Team
1 Evolve Biosystems, Davis, CA, United States, 2Department of Food Science and Technology, University of Nebraska,
Lincoln, NE, United States, 3Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada,
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Toll-like receptors (TLRs) play a crucial role in innate immunity and provide a first line of
host defense against invading pathogens. Of the identified human TLRs, TLR10 remains
an orphan receptor whose ligands and functions are poorly understood. In the present
study, we sought to evaluate the level of TLR10 expression in breast milk (BM) and explore
its potential function in the context of HIV-1 infection. We evaluated HIV-1-infected
(Nigerian: n = 40) and uninfected (Nigerian: n = 27; Canadian: n = 15) BM samples
for TLR expression (i.e., TLR10, TLR2, and TLR1) and report here that HIV-1-infected
BM from Nigerian women showed significantly higher levels of TLR10, TLR1, and
TLR2 expression. Moreover, the level of TLR10 expression in HIV-1-infected BM was
upregulated by over 100-fold compared to that from uninfected control women. In vitro
studies using TZMbl cells demonstrated that TLR10 overexpression contributes to higher
HIV-1 infection and proviral DNA integration. Conversely, TLR10 inhibition significantly
decreased HIV-1 infection. Notably, HIV-1 gp41 was recognized as a TLR10 ligand,
leading to the induction of IL-8 and NF-κBα activation. The identification of a TLR10
ligand and its involvement in HIV-1 infection enhances our current understanding of HIV-1
replication and may assist in the development of improved future therapeutic strategies.
Keywords: human breast milk, HIV-1, gp41, p17, p24, TLR10, IL-8, NF-κBα
INTRODUCTION
Toll-like receptors (TLRs) are the most well-known and researched family of pattern recognition
receptors (PRRs) that recognize conserved regions of pathogen-associated molecular patterns
(PAMPs) and endogenous danger-associated molecular patterns (DAMPs) responsible for driving
cellular activation central to innate immunity. To date, 10 TLRs have been identified in humans,
with TLR10 being the only remaining family member without a clearly defined ligand (1,
2); however, a number of ligands, including synthesized TLR2 ligands (i.e., Pam3CSK4 and
PamCysPamSK4), have been identified as potential TLR10 PAMPs through computational protein
modeling (3).
Once believed to be only preferentially expressed on various types of immune cells (4), TLR10
has now been identified in multiple mucosal sites, including the small intestine, fallopian tubes,
eye, and stomach (5–8). Interestingly, many of these sites are also highly affected during acute viral
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infections, including HIV-1; therefore, identifying ligands for
TLR10 and defining the mechanisms of host defense following
viral infection is of particular interest for the development of
novel vaccines and drug therapies.
Immune activation is critical to HIV-1 infection and
pathogenesis, leading to increased proinflammatory cytokine
production, T cell exhaustion, and the eventual development
of opportunistic infections (9); however, our understanding of
immunopathogenesis remains incomplete. Historically, research
has focused on HIV-1-specific adaptive immune responses,
whereas the role of innate immunity has been largely overlooked,
despite the fact that it provides the first line of defense and shapes
subsequent adaptive responses. Although the identification of
HIV-1 PAMPs recognized by PRRs remain poorly elucidated,
data indicate that peripheral blood mononuclear cells (PBMCs)
and plasmacytoid dendritic cells (pDCs) derived from HIV-1
infected individuals have increased levels of TLR2, TLR3, TLR4,
TLR6, TLR7, and TLR8 mRNA at various stages of disease
progression (10, 11). In addition, our laboratory has previously
investigated the genital epithelium of Kenyan commercial sex
workers and found significant modification in TLR expression,
which correlates with resistance to HIV-1 (12). Furthermore, we
were the first to demonstrate that soluble TLR2 (sTLR2), which
is highly prevalent in human breast milk (BM) (13) serves as
an innate antiviral factor in BM and significantly inhibits HIV-
1 infection and integration in vitro (14, 15). We further reported
a significant increase in TLR2 expression in BM cells, and that
the overexpression of TLR2 in reporter cells greatly enhanced
HIV-1 infection in vitro (15). We further identified HIV-1-
specific structural proteins, p17, p24, and gp41, which serve as
PAMPs, leading to significantly increased immunopathogenesis
and infection in vitro (16).
Given that TLR10 is a homolog of both TLR2 and TLR1,
we hypothesized that TLR10 is involved in sensing specific
HIV-1 structural proteins, which leads to increased cellular
activation and HIV-1 infection. In this study, we report highly
significantly increased TLR10 and TLR1 expression in HIV-1-
infected human primary BM cells. Additionally, for the first
time, TLR10 was found to be involved in innate immune sensing
and cellular activation induced by HIV-1, leading to increased
infection in vitro. Taken together, we provide clear evidence
that specific HIV-1 structural proteins trigger TLR10-dependent
cellular activation. These findings indicate that TLR10 and its
heterodimers, TLR1 and TLR2, play a central role in the innate
immune response to HIV-1 infection by sensing viral proteins,
leading to increased immunopathogenesis.
RESULTS
Healthy Human BM Derived Macrophages
and Mammary Epithelial Cells Express
TLR10, TLR2, and TLR1
Depending on the stage of lactation, the predominant cell types
in BM consist of a variety of leukocytes in colostrum (4 ×
106 cells/mL) and mature BM (105-106 cells/mL), as well as
mammary epithelial cells (MECs) (16–18). The majority of
leukocytes present in BM display an activated phenotype (19)
and are comprised primarily of macrophages (55–60%) and
neutrophils (30–40%), with the remaining 5–10% composed
of lymphocytes (∼65% CD8+ T cells, 15% CD4+ T cells,
and 20% B cells) (18). Macrophages and MECs are thought
to facilitate mother-to-child transmission (MTCT) of HIV-1,
and both cell types express several canonical HIV-1 receptors,
(e.g., CD4 and CCR5), readily endocytose cell-free HIV-1, and
can function as a viral reservoir (20). To explore how TLR
expression is linked to HIV-1 infection, we first analyzed the
phenotype of the macrophages and MECs present in HIV-1
uninfected human BM using flow cytometry. We found that the
majority of cells that were CD14+ and CD45+ (>10%) expressed
TLR1 (3.03%), TLR2 (58.6%), and TLR10 (99.3%). Similarly,
MUC1+ (75.4%) MECs also expressed TLR1, TLR2, and TLR10
exhibiting 3.67, 69.1, and 0.39%, respectively (Figure 1). Based
on our flow cytometry data our findings suggest that BM derived
macrophages predominantly express TLR10 which implies that
these cells may play an important role in innate immunity against
invading pathogens in suckling infants.
TLR10 and TLR1 Are Highly Expressed in
HIV-1 Infected Human Primary BM Cells
The biological relevance of primary BM cells in HIV MTCT
remains unclear. BM derived TLRs such as TLR2, TLR3, and
TLR5 along with other bioactive molecules are known to
play an important role in intestinal protection, inflammatory
responses and even microbial recognition (21). Indeed, it has
been suggested that certain cytokines such as interferon gamma
secreted by primary BM cells reduce the rate of BM transmission
of HIV-1 in breastfeeding infants (22, 23); therefore, we next
sought to determine the level of TLR10 and TLR1 expression
in BM collected from HIV-1 infected women from Nigeria and
compared to HIV-1 uninfected women. Both HIV-1 infected as
well as uninfected control women were recruited from Plateau
State, Nigeria and a series of BM samples from first week to 52
weeks postpartum were collected and shipped to Canada. All
HIV-1 positive women were on antiretroviral therapy (ART) and
receiving antiretroviral drugs according to the regimen set by
Nigerian Government and world Health Organization (WHO) as
described (24) We evaluated HIV-1-infected (Nigerian: n = 40)
and uninfected (Nigerian: n= 27; Canadian: n= 15) BM samples
for the expression of TLR10 and TLR1. Our results clearly
demonstrated a highly significant increase in the expression
of both TLR1 and TLR10 cDNA in HIV-1-infected compared
to uninfected primary BM cells from the same geographical
location (Figure 2; P = 0.0006 and P < 0.0001, respectively).
Specifically, TLR10 expression was ∼100-fold higher in HIV-1
infected vs. HIV-1 uninfected primary BM cells. In addition to
HIV-1 infected and uninfected women from Nigeria, we also
collected BM samples from uninfected healthy women from
Hamilton region, Ontario, Canada and compared their TLR1
and TLR10 expression levels with uninfected healthy control
women from Nigeria. Interestingly, it was found that TLR1 and
TLR10 expression on Nigerian HIV-1 uninfected primary BM
cells was significantly lower compared to that on CanadianHIV-1
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FIGURE 1 | Flow cytometry analyses of TLR1, TLR2, and TLR10 expression in the two major types of primary BM cells obtained from HIV-1 uninfected women at 3
months post-partum. Leucocytes were gated with CD45-PerCP-Cy5.5 and CD14-V450 whereas the epithelial cells were gated with MUC1-PE-Cy7 and CD45-. The
antibodies TLR1-APC TLR2-APC and TLR10-PE were separately used to detect TLR1, TLR2, and TLR10 in CD14+-CD45+-MUC1− and MUC1+-CD45− cell types
to differentiate the two major constituents of BM. Representative images are shown with TLR1, TLR2, and TLR10 expression depicted as percentages on right corner
of each image.
uninfected primary BM cells thus highlighting the demographic
differences. Taken together, these results show that TLRs are
highly expressed on primary BM cells, and this expressionmay be
closely associated with an individual’s HIV-1 infection and innate
immune status.
The Level of TLR10 Expression
Significantly Alters HIV-1 Infection
and Integration
Since the extracellular expression of TLR10, TLR1, and TLR2
are innate immune molecules involved in pathogen signaling
and are highly expressed on cells in BM (Figures 1, 2) and
PBMCs (1, 25) we decided to utilize human mammary
epithelial (Michigan Cancer Foundation-10A; MCF-10A)
cells and macrophage cell lines (human acute monocytic
leukemia; THP-1) for further downstream experiments.
MCF-10A is a human non-tumorigenic epithelial cell line
with no signs of terminal differentiation and has been used
in our previous studies (15). THP-1 is an immortalized
monocyte-like cell line derived from the peripheral blood
of a childhood case of acute monocytic leukemia (26, 27)
and has been utilized previously (28). First we determined
whether the expression levels could influence HIV-1 infection
in vitro. For this purpose, HIV-1 reporter TZMbl cells (29)
were transiently transfected alone or in combination with
plasmids overexpressing TLR10 and the heterodimers, TLR2
and TLR1 (Figure 3A), followed by HIV-1 infection and
measurement of luciferase activity. The results showed a
significantly increased rate of HIV-1 infection in TZMbl
cells overexpressing TLR10 and heterodimers TLR1 or TLR2
compared to the empty vector alone, uninfected control or
a T20 control (Enfuvirtide; HIV-1 fusion inhibitor) (30, 31)
(Figure 3A; P < 0.05). In addition, HIV-1 infection was
significantly elevated in TZMbl cells, which were either co-
transfected with TLR1/10 or TLR2/10 compared to the control
(Figure 3A; P < 0.05).
Next, we determined the extent of HIV-1 infection in TLR10
and TLR2 stable reporter cell lines. TZMbl-T2 and TZMbl-T10
displayed significantly higher levels of proviral DNA compared
to TZMbl cells, which served as a control (Figure 3B; P <
0.05). Furthermore, stable TZMbl-T2 transiently over-expressing
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FIGURE 2 | Significantly elevated expression level of TLR1 and TLR10 in HIV-1 infected human primary BM cells. Expression of TLR1 and TLR10 as measured by
qRT-PCR with the mRNA extracted from primary BM cells collected from HIV-1 negative Hamilton, Canada women (HIV-N Hamilton) and Nigerian HIV-1 negative
(HIV-N) and HIV-1 positive (HIV-P) women. TLR1 expression is shown on right (p = 0.0006) whereas TLR10 expression is shown on left (p < 0.0001).
FIGURE 3 | Overexpression or siRNA mediated knockdown of TLR10 significantly alters HIV-1 infection and integration (A) HIV-1 infection was significantly enhanced
in HIV-1 reporter TZMbl cells transiently overexpressing TLR10 alone and co-transfected with TLR2 or TLR1 expression plasmids by measuring luciferase activity in
relative light units (RLU). (B) HIV-1 integration was significantly increased in stable TZMbl reporter cells overexpressing TLR10, TLR2, and TLR1. TZMbl, TLR2- stable,
and TLR10-stable cells were used for co-transfection with plasmids: empty vector, TLR2, TLR10, and TLR1 vector, TLR10 and TLR1 vector, and TLR2 and TLR1
vector. Proviral DNA (DNA pol) was detected by PCR and normalized to the 18S rRNA gene. (C) Proviral DNA was obviously decreased in macrophages with TLR10
knocked down prior to HIV-1 infection. T20: Enfuvirtide, an HIV-1 fusion inhibitor used as a negative control. Data set is representative of three different experiments
completed in triplicate (Statistic marks in the plots: *p < 0.05, **p < 0.01 for Mann Whitney t-tests, each group compared to the vector group in A and B, or to the
control group in C; pair comparison ∧, # in B, respectively).
TLR10 or TLR1 also enhanced HIV-1 pol gene expression.
Similarly, stable TZMbl-T10 cells transiently over-expressing
TLR2 or TLR1 also enhanced proviral pol DNA at 8 h post-
infection compared with the empty vector-transient stable cells
(Figure 3B; P < 0.05).
In order to observe the HIV-1 infection in susceptible cells,
macrophages were differentiated from THP-1 cells to determine
whether siRNA-mediated knockdown of TLR1, 2 and/or 10 for
2 days prior to CCR5-tropic HIV-1 (BAL strain) exposure for
7 days would affect the HIV-1 infection rate. THP-1 cells were
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first transfected with siRNAs targeting TRL1, TLR2, or TLR10,
and their knockdown was confirmed by Western blot. TLR1 and
TLR2 knockdownwas complete compared to TLR10 where it was
partial (Supplementary Figure 1). After the confirmation of the
siRNA-mediated knockdown, HIV-1 integration was determined
by PCR, which showed significantly decreased proviral DNA
production in the cells that received siRNAs against TLR1,
TLR2, TLR10, or combinations of TLR2 with TRL10 or TLR1
compared to the control siRNA (Figure 3C). In addition, since
we observed incomplete TLR10 knockdown in THP-1 cells,
it is likely that upon complete knockdown of TLR10, HIV-
1 integration and proviral DNA production will be impacted.
Together, these data indicate that the expression of TLR1, 2 and
TLR10 alone or in combination significantly enhances HIV-1
infection and integration in vitro. Moreover, based on TLR10
and TLR2 co-transfection or co-depletion through siRNA and
effect on HIV-1 infection or integration, TLR10 appears to
play a role in HIV-1 infection and integration independent of
TLR2 since no additive effect of TLR10 and TLR2 was observed
(Figures 3B,C). Therefore, it is highly likely that TLR2 and
TLR10 are independently involved in the regulation of HIV-1
infection in a non-heterodimeric form.
Expression of TLR10, TLR1, and TLR2 Is
Up-Regulated by PAMPs and HIV-1
We next determined whether the expression of TLR1, 2, or
10 changes in response to various TLR ligands. MCF-10A,
THP-1, and primary BM cells were stimulated with TLR
ligands of interest at the following doses: 100 ng/mL Pam3Cys-
Ser-(Lys)4 (Pam3CSK4); 10 ng/mL lipopolysaccharide (LPS),
ssRNA40 1µg/mL, and cell-free HIV-1 overnight. Total RNA
was isolated from the cells and qRT-PCR was performed. Data
showed that compared to medium control, MCF-10A cells
exposed to the TLR2/1 ligand, Pam3CSK4, significantly increased
the level of TLR1, 2, and 10 expression (Figure 4A). Similarly,
exposure to TLR4 ligand, LPS, significantly increased TLR1 and
2 expression (Figure 4A). In contrast, although ssRNA40 showed
a significant increase in TLR1 and TLR10, but had no significant
effect on TLR2 expression (Figure 4A). Conversely, HIV-1
exposure significantly increased the level of TLR10 expression
on MCF-10A cells (Figure 4A) despite the fact that HIV-1
does not productively infect this cell type (20). In THP-1 cells,
Pam3CSK4 exposure significantly increased the level of TLR2
and 10 expression, whereas LPS exposure resulted in an increase
in TLR1 and 2 expression (Figure 4B). Following exposure to
ssRNA40, the expression of TLR1, 2, and 10 was significantly
increased. Similarly, HIV-1 exposure significantly increased the
level of TLR1, 2, and 10 expression in THP-1 cells (Figure 4B).
Primary BM cells exposed to specific PAMPs also exhibited
significantly increased levels of TLR1 and TLR2 expression
following exposure to Pam3CSK4 and LPS (Figure 4C). Elevated
TLR2 expression was also observed after exposure to ssRNA40
and cell-free HIV-1 (Figure 4C). Most importantly, the data
indicated that TLR10 was significantly elevated after exposure
to ssRNA40 and HIV-1 (Figure 4C). Taken together, these data
indicate that specific HIV-1 PAMPs, as well as cell-free HIV-
1, significantly increase TLR10, TLR1, and TLR2 expression in
primary BM cells.
HIV-1 Proteins Regulate TLR Expression
Levels and Induce IL-8 Secretion
HIV-1 structural proteins and glycoproteins have been detected
in BM (15) and have been shown to exert immunological effects
typical of a proinflammatory response (32–37). Based on our
recent findings that HIV-1 structural proteins bind to TLR2
(16), we hypothesized that HIV-1 components may contact the
cell surface and trigger TLR10 signaling. Therefore, we next
investigated whether specific HIV-1 structural proteins increased
cellular activation in primary BM cells. To characterize which
HIV-1 structural proteins were involved in this process, we used
purified p17 (200 ng/mL), p24 (200 ng/mL), gp41 (1µg/mL),
and gp120 (1µg/mL) to treat MCF-10A and THP-1 cells and
detected the cellular responses. The results demonstrated that
the expression of TLR10 and TLR2 mRNA was significantly
altered following exposure to gp41 alone compared to untreated
medium, as well as Pam3CSK4, which served as a positive
control inMCF-10A cells (Figure 5A). IL-8 production increased
in a dose-dependent manner in the supernatants of MCF-
10A cell cultures containing gp41 and Pam3CSK4 (Figure 5B).
However, TLR10 was significantly highly expressed in THP-
1 cells in the presence of gp41 as well as p17 (Figure 5C).
TLR2 and TLR1 were obviously increased in the presence
of gp41, p17, and p24. In the THP-1 cell culture, IL-
8 was also correspondingly produced with increases in the
amount of Pam3CSK4 and structural proteins, except gp120
(Figure 5D). Together, this data indicates that HIV-1 gp41
is able to induce the innate immune response and alters
the level of TLR10 expression, similar to TLR2 (16) and is
not cell-type-sensitive.
Furthermore, we confirmed our observations by transfecting
THP-1 cells with siRNA specific to target genes (Figure 6A).
Compared to the cells treated with the control siRNA,
TLR10 siRNA suppressed more than 3-fold of IL-8 production
in the cells treated with HIV-1 PAMPs. Treatment with
TLR2 siRNA decreased IL-8 production by ∼2-fold. The
combination of TLR10 and TLR2 siRNAs decreased IL-8
production more than 2-fold. In addition, we used antibodies
to neutralize TLR10, TLR2, and TLR1 in gp41 and p17-
treated THP-1 cells. As shown in Figure 6B, treatment with
anti-TLR10 and TLR1 antibodies significantly reduced IL-
8 production in gp41- and p17-treated cells, respectively.
Anti-TLR2 antibodies exhibited a similar trend but without
a statistical difference. Since the primary focus of this
study was TLR10-related events, we only used anti-TLR10
antibodies to treat MCF-10A cells in the neutralization
experiments. The results revealed that gp41-induced IL-8
production was also significantly decreased in the presence
of the anti-TLR10 antibody (Figure 6C). Similarly, primary
BM cells were incubated with the anti-TLR10 antibody before
treatment with HIV-1 proteins. The data revealed that gp41-
induced IL-8 production was also significantly decreased
in the presence of TLR10 antibodies in primary BM cells
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FIGURE 4 | Effects of PAMPs and HIV-1 on the level of TLR expression in cell cultures. (A) qRT-PCR of TLR10, TLR2, and TLR1 mRNA from MCF-10A cells treated
with TLR2 PAMP Pam3CSK4, TLR4 PAMP LPS, TLR7/TLR8 PAMP ssRNA40, and cell-free HIV-1 BAL. (B) q-RT-PCR in THP-1 cells. (C) qRT-PCR in primary BM
cells. Data set is representative of three different experiments completed in triplicate. Statistic marks: *p < 0.05, **p < 0.01 for the Mann-Whitney t-tests, each group
compared to medium-treated group (Medium).
(Figure 6D). These results suggest that HIV-1 gp41 is capable of
upregulating both TLR2 (15) and TLR10 in all cells under our
experimental conditions.
HIV-1 Proteins Induce TLR10, TLR2, and
TLR1 Signaling Through the Activation
of NF-κBα
TLR2 and TLR1-mediated signaling pathways have been well-
studied. We have recently discovered that the HIV-1 structural
proteins p17, p24, and gp41 directly interact with TLR2, inducing
NF-κBα activation. We then asked whether these structural
proteins also induce NF-κBα activation via their PAMP effects on
TLR10. Cells were treated with Pam3CSK4, p17, p24, and gp41,
followed by a Western blot of the lysates with anti-phospho-
IκBα, a subunit of NF-κBα that is representative of active NF-
κBα. The results in Figure 7A demonstrate that activated NF-
κBα was substantially expressed in MCF-10A cells treated with
gp41, compared to the positive control (Pam3CSK4) and negative
control (medium)-treated cells. In contrast, moderate expression
of P-IκBα was observed in the MCF-10A cells treated with
p17. However, in both the macrophages derived from THP-1
and BM cells, the three HIV-1 proteins greatly stimulated the
production of active NF-κBα. In addition, translocation of the
NF-κBα p65 subunit into the nuclei occurred in MCF-10A cells
treated with Pam3CSK4 and gp41 (Figure 7B). p65 translocation
was observed in a number of MCF-10A cells in the presence
of p17 and p24. Compared to the medium control, treatment
with Pam3CSK4 and each of the three HIV-1 proteins led to p65
translocation to the nuclei of THP-1 cells.
When TLR10 expression was knocked down using
siRNA, NF-κBα activation in response to HIV-1 proteins
was significantly reduced in THP-1 cells (Figure 8). The
signaling activity induced by the ligation of TLR2 and TLR1 by
the positive siRNA control was similar to the response induced
by TLR10 activation by the three HIV-1 proteins (p17, p24,
and gp41), suggesting that these proteins are involved in the
activation of NF-κBα. Considering the possibility that endotoxin
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FIGURE 5 | Effects of HIV-1 proteins on TLR expression and cellular responses. (A) MCF-10A cells were treated with Pam3CSK4 and the HIV-1 structural proteins:
p17, p24, gp41, and gp120. Cellular TLR10, TLR2, and TLR1 mRNAs were analyzed by qRT-PCR. (B) IL-8 production in cell culture supernatants in the presence of
different concentrations of Pam3CSK4 and HIV-1 proteins were analyzed by ELISA. (C) The expression of TLR mRNAs analyzed by qRT-PCR in THP-1 cells treated
with Pam3CSK4 and the HIV-1 structural proteins: p17, p24, and gp41. (D) IL-8 production in THP-1 cell culture supernatants in the presence of different
concentrations of Pam3CSK4 and HIV-1 proteins was analyzed by ELISA. Data set is representative of three different experiments completed in triplicate. Statistic
marks: *p < 0.05, **p < 0.01 for the Mann-Whitney t-tests, each group was compared to the medium-treated group (Medium).
was present in the HIV-1 products, we used TLR4 siRNA in the
same experiment. The Western blot results clearly showed that
knocking down TLR4 did not change the cellular response to
p17 and gp41 in activating NF-κBα, which excluded endotoxin
or LPS contamination in the two proteins. A 50% reduction in
NF-κBα activation was observed in TLR4 siRNA transfected cells
treated with Pam3CSK4 and p24, thus indicating cross-talk and
a convergence between the different TLR signaling pathways.
DISCUSSION
To date, a total of 10 (1–10) human TLRs have been identified,
which are known to play an important role in the innate immune
sensing of invading pathogens (38, 39). Although the ligands for
TLRs 1 through 9 are well-known, TLR10 has remained the only
orphan receptor with no known ligand, despite being identified
>17 years ago (4). To our knowledge, we are the first to report
that TLR10 is involved in HIV-1 infection and most importantly,
that gp41 acts as a ligand for TLR10 in human macrophages
and MECs.
We initially attempted to identify and screen TLRs present
in human BM and previously reported that soluble TLR2
(sTLR2) is present in human BM and significantly inhibits HIV-
1 infection (15). Furthermore, we also showed that the HIV-1
structural proteins, p17, p24, and gp41, serve as PAMPs for TLR2,
leading to the activation of the NF-κBα signaling pathway (16).
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FIGURE 6 | HIV-1 proteins, p17 and gp41 elicit cellular responses through sensing TLR10, TLR2, and TLR1. IL-8 production stimulated by Pam3CSK4, p17, p24,
and gp41 was greatly suppressed in THP-1 cells knocked-down of TLR10 with specific siRNA (A) and THP-1 cells neutralized with anti-TLR10 antibody (B). (C) IL-8
stimulated by Pam3CSK4 and gp41 was reduced in MCF-10A cells neutralized with an anti-TLR10 antibody. (D) Primary BM cells displayed a significant decrease in
IL-8 production induced by HIV-1 gp41 following neutralization with an anti-TLR10 antibody. Data set is representative of three different experiments completed in
triplicate. Statistic marks: *p < 0.05; **p < 0.01 for Mann Whitney t-tests, with each group compared to the medium treated group (Medium).
Surprisingly, with the exception of TLR1 and TLR2, we found
significantly higher levels of TLR10 (>100-fold) expression in
BM samples collected from HIV-1 infected Nigerian women
(Figure 2), thus indicating that TLR10 might play an important
role in HIV-1 infection and pathogenesis. In addition, uninfected
BM samples from Canadian women exhibited higher basal levels
of TLR10 and TLR1 expression compared to uninfected Nigerian
women. Although whether there is a significant difference in
the level of these two TLRs in healthy populations remains
unknown, it is tempting to speculate that the genetic differences
present in these two populations might affect the outcome of
HIV-1 infection.
TLR1, TLR6, and TLR10 share a common locus on
chromosome 4p14 and are structurally similar to each another
(40) and are thought to have arisen from several gene duplication
events (41). Furthermore, it has been established that TLR10,
TLR1, and TLR6 form a single cluster and provide an important
first line of defense against infectious agents. Previous work
related to TLR1, TLR2, TLR6, and TLR10 has failed to provide
the agonist for TLR10 but suggests that the TLR10 ligand might
be of a viral origin, leading to the activation of NF-κBα (40, 42).
Our current study confirms that one ligand for TLR10 is indeed
of viral origin, notably HIV-1 gp41.
TLR10 is known to possess point mutations in its TIR
domain that play a critical role in its proper functioning (43).
Furthermore, it has been shown that genetic variations in
TLR10 can lead to various ailments, such as Crohn’s disease
(44) and asthma (45). Moreover, TLR10 has been shown to
be involved in osteoarthritis (46), Crimean Congo hemorrhagic
fever (47), Listeria monocytogenes, Salmonella Typhimurium
(28), Helicobacter pylori (7), and influenza (2). Nevertheless, the
involvement of TLR10 in various diseases paves the way for
future exploratory studies.
Interestingly, recent data concerning early hominins,
Neandertals, and Denisovans, who lived in Europe and
Western Asia for over 200,000 years, likely interbred and
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FIGURE 7 | HIV-1 proteins lead to NF-κBα activation (A) Western blot analysis of the cell lysates extracted from MCF-10A, THP-1, and primary BM cells treated with
HIV-1 proteins and detected with an antibody against the active NF-κBα subunit, phospho(P)-IκBα, with anti β-actin used as the loading control on the same
membranes (B) Confocal microscopy of HIV-treated MCF-10A and THP-1 cells fixed and stained with an anti- NF-κBα subunit p65 antibody and visualized with a
second antibody, anti-rabbit-IgG-alexa488 (GFP; green), p65 was translocated upon activation into the nuclei (RFP; red with propidium iodide staining) displayed in
yellow (Merged).
contributed advantageous genetic alleles to the immune systems
of modern humans (48–50). Indeed, TLR genes, which are
critical components of innate immunity, have also gained
advantageous alleles through this mixing of the gene pool.
Notably, adaptive introgression and local positive selection led
to the significantly increased expression of the TLR6, TLR1, and
TLR10 genes, which facilitated resistance to infectious diseases
but may also be associated with increased hypersensitivity to
non-pathogenic allergens.
Primary BM cells, MCF-10A MECs, and macrophages display
significantly higher levels of TLR10 expression in response to
HIV-1. In particular, gp41, not p17, and p24, was able to act as a
ligand for TLR10. Since primary BM cells express TLR2, TLR1,
and TLR10 (Figures 1, 2); thus, it is plausible that these TLRs
could form heterodimers.
Our data have shown that macrophages and MECs are
human BM constituents that express TLR1, TLR2, and
TLR10. Although gp41 was found to act as a ligand for
both TLR2 (16) and TLR10 in the current study. Whether
TLR2 and TLR10 interact and associate with each other
in the context of an HIV-1 infection remains unclear and
will be intriguing to investigate in future studies. However,
since macrophages derived from THP-1 cells sensed gp41
in addition to p17 and p24, it is suggested that BM
derived macrophages actively participates in HIV-1-induced
innate immunity.
Although the induction of TLR10 by immune cells (e.g., B-
cells, plasmacytoid dendritic cells, and macrophages) is well-
reported (28, 40); the induction of TLR10 by non-immune cells
(e.g., intestinal epithelial cells or MECs) raises the possibility of a
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FIGURE 8 | siRNA mediated knockdown or antibody mediated blocking of TLR10 inhibits NF-κBα activation induced by HIV-1 proteins (A) anti-TLR10 antibody
decreased gp41 induced P-IκBα by half in MCF-10A cells. (B) TLR10 siRNA ablated the induction of P-IκBα by gp41 in THP-1 cells.
conserved mechanism regarding TLR10 expression by epithelial
cells (28).
We suggest that TLR10 and TLR1 both work cooperatively
as the transfection of TRL10 and TLR1 alone or in combination
significantly enhanced HIV-1 infection, indicating that TLR10
and TLR1 likely form heterodimers. This is evidenced by
the observation that a depletion of TLR10 by a siRNA-
mediated knockdown negatively impacted the proviral
integration of HIV-1. Moreover, TLR10 knockdown led
to significantly lower levels of IL-8 production in cells
treated with gp41, p17, and p24. Furthermore, gp41, p17,
and p24 were able to activate NF-κBα, which was readily
blocked using an anti-TLR10 antibody or TLR10-specific
siRNA-treated cells, suggesting that TLR10 signaling led
to the activation of NF-κBα and ultimately the production
of IL-8.
Importantly, the present study provides the first evidence that
HIV-1 gp41 functions as a ligand for TLR10 in MCF-10A and
THP-1 cells. Recently, double-stranded RNA (dsRNA) has been
shown to act as a ligand for TLR10 (51). In addition, the same
study demonstrated that TLR10 competes with TLR3 for binding
to ligands in various endocytic pathways, ultimately leading to
the induction of interferons. Similarly, synergy between TLR3
and TLR10 has been suggested in the context of an influenza
virus infection. Although our current data demonstrates the
involvement of TLR10 in HIV-1 infection, the existence of such
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synergy between TLR10 and TLR3 in an HIV-1 infection cannot
be dismissed and requires further future investigation.
Our data demonstrated that HIV-1 gp41 acts as a ligand for
TLR10 and leads to the induction of IL-8 and NF-κBα activation.
However, our observation is contradictory to some previous
reports where TLR10 expression has been shown to suppress the
cytokine responses (1, 52). These contradictions could be due
to differences in cell-type use, ligand specificity or geographical
location. Further, divergent roles of TLR10 have been suggested
to be due to the mechanism of cross-talking between TLR10 and
TLR3 (51) or perhaps the interaction of TLR10 with TLR2, TLR1
and TLR6 (1). Although, the exact mechanism is not known; we
cannot exclude the possibility of spontaneous heterodimerization
of TLR2 and TLR10 (1) due to HIV-1 gp41 which acts as a ligand
for both TLR2 (16) and TLR10.
The present investigation demonstrated that TLR10 acts as
an innate immune sensor for HIV-1 infection and leads to the
induction of IL-8. Furthermore, we showed that blocking TLR10
with either an anti-TLR10 antibody or siRNA attenuates gp41-
mediated NF-κBα activation (Figure 8). Interestingly, TLR1
depletion through siRNA knockdown also inhibited gp41-
mediated NF-κB activation, suggesting that TLR1 and TLR10
might form a heterodimer. Recent evidence shows that TLR10
plays a key role in the innate immune response following
an influenza infection (2). Specifically, it was found that
silencing of the TLR10 gene impacted IL-8 production in human
influenza virus-infected macrophages. Similarly, we observed
that when TRL10 is silenced in HIV-1 infected macrophages,
IL-8 production is severely impaired, thus raising the possibility
that there is a conserved mechanism during HIV-1 and influenza
virus infections in human macrophages.
Our studies have shown that human primary BM cells express
significantly higher levels of TLR1, TLR2, and TLR10. Currently,
the precise role of these TLRs in infants following BM ingestion
remains unknown. However, in our other ongoing studies, we
have identified some novel exosomal miRNAs in BM samples
exclusive to HIV-1 infection present in mother’s milk (data not
shown) that could potentially play a protective role duringMTCT
of HIV-1 in conjunction with these TLRs.
Taken together, our data reveal for the first time that TLR10 is
involved in HIV-1 infection. Furthermore, gp41 was found to act
as a novel ligand for TLR10.We believe that the data shown in the
present study describing an HIV-1 ligand for TLR10 will advance
our current knowledge, as well as further our understanding of
the role of TLR10 in innate immunity during HIV-1 infection.
MATERIALS AND METHODS
Human Subjects
HIV-1-uninfected (Hamilton, Ontario, Canada and Nigeria) and
HIV-infected (Nigeria) women were recruited to participate in
the present study. All HIV-infected women were in the chronic
phase of infection as determined by at least two positive HIV-
1 serological tests separated by at least 1 year. All women
were sampled during voluntary “healthy” research visits as per
the cohort protocol, and therefore, were not acutely ill at the
time of assessment. Written as well as informed consent for
the collection of demographics, behavioral data and biological
samples were obtained from all study participants. Inclusion
criteria included breastfeeding women who were HIV-uninfected
and did not report complications in utero during their full-term
pregnancies or intrapartum. Women were excluded if they had
cesarean sections, their pregnancies were not full-term, or they
were diagnosed with mastitis post-partum. Samples included
in these analyses were obtained from women who were not
taking medications other than vitamin supplements intra- or
post-partum and did not receive an epidural intra-partum. Three
mothers reported minor colic and one reported silent reflux in
their infants. The study was approved by the institutional review
boards of the University of Manitoba Hospital ethical review
committee. All clinical investigations were conducted according
to the principles of the Helsinki Declaration. The study was
approved by theMcMaster Research Ethics Board (REBApproval
#08-176) and the CCI of Children’s Hospital, Los Angeles.
Sample Acquisition and Preparation
Milk samples were self-collected into sterile tubes within the
first week and at 1, 3, and 6 months post-partum, and
immediately shipped on ice for processing in our laboratory.
The samples were separated into lipid, supernatant, and cellular
fractions and stored at −80◦C and liquid nitrogen, respectively.
BM supernatant fractions were used for Western blotting or
were filter-sterilized (0.45µm) for functional assays to avoid
cellular contamination.
Cells and Reagents
THP-1 and primary BM cells were cultured in RMPI-1640
supplemented with 10% FBS, 2mM L-glutamine, 10mM
HEPES, 1mM Sodium Pyruvate, and 1% penicillin/streptomycin
(Invitrogen). MCF-10A cells (American Type Culture Collection,
Manassas, VA) were maintained in Dulbecco’s modified Eagle’s
medium-F12 (DMEM/F12, Invitrogen) supplemented with 5%
horse serum (Invitrogen), 100 ng/mL cholera toxin (Sigma),
10µg/mL insulin (Sigma), 20 ng/mL recombinant human
EGF (Peprotech), 0.5µg/mL hydrocortisone (Sigma), and 1%
penicillin/streptomycin (Invitrogen). The TZMbl cells were
cultured in DMEM supplemented with 10% FBS and 1%
(vol/vol) each of L-glutamine, penicillin, and streptomycin
with and without 0.8 mg/mL geneticin (G418; Invitrogen,
Burlington, ON, Canada), respectively, as described previously
(16, 29). HIV-1 proteins included p17 (Virogen, Mississauga,
ON, Canada), p24, and gp41 (Genway Biotech, Inc., San Diego,
CA, USA). TLR ligands, ssRNA40 (Mobix,McMaster University),
LPS, Pam3CSK4 (InvivoGen), and poly I:C (Sigma-Aldrich,
Burlington, ON, Canada) were diluted in phosphate-buffered
saline (PBS).
Quantitative Reverse-Transcriptase
Real-Time Polymerase Chain Reaction
Total RNA was extracted from the cells using Trizol as per
the manufacturer (Invitrogen, Carlsbad, California, USA) and
treated with DNase I, DNA-free (Ambion, Austin, Texas, USA).
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Reverse transcription (RT) reactions and quantitative real-time
PCR (qRT-PCR) was performed as previously described (11).
Small Interfering RNA Knockdown
siRNA molecules targeting human TLR1 (Sigma-
Aldrich, SASI_Hs01_00162170/AS), TLR2 (Sigma-Aldrich,
SASI_Hs01_ 00081589/AS), TLR4 (Sigma-Aldrich,
SASI_Hs01_00122250/AS), TLR10 (Sigma-Aldrich,
SASI_Hs01_00099892), or non-targeting siRNA (Invitrogen,
129201 H07/129296 H05) were purchased and used as previously
described (16). The cells were exposed to specific HIV-1
proteins, and the supernatants were collected to quantify the
level of pro-inflammatory cytokine production as previously
described (16).
Flow Cytometry
Flow cytometry analysis was performed as previously described
(53). Briefly, 10mL of fresh healthy human BM containing
∼5 × 106 cells collected within 3 months of lactation, was
centrifuged at 2,000× g at room temperature for 10min, washed
with PBS, and centrifuged two more times. The cells were first
incubated with Live/Dead Fixable Aqua (ThermoFisher) at room
temperature for 30min and subsequently washed twice with PBS.
Besides compensation and FMO controls, two sets of cells were
immune-stained at room temperature for 30min in 0.5% BSA-
PBS containing a combination of conjugated antibodies (CD45-
PerCP-Cy5.5 BD, CD14-V450 BD, MUC1-PE-Cy7 BioLegend,
TLR2-APC R&D Systems, TLR10-PE BioLegend) and (CD45-
PerCP-Cy5.5, CD14-V450, MUC1-PE-Cy7, TLR1-APC R&D
Systems, TLR10-PE), respectively. The cells were washed twice
with PBS and fixed with 1% PFA-PBS. The samples were run on a
BD LSRFortessa and analyzed using FlowJo software.
Establishment of a Stable TLR10 Reporter
Cell Line
The TLR10 expression plasmid, pIhT10G, was subcloned
from pUNO1-hTLR10 (InvivoGen) into pIRES2-Green1 vector
(Clontech), with a SacI-BamHI fragment via PCR using Phusion
DNA polymerase (New England Biolabs, USA). Transfection
with 2.5 µg pIhT10G and 5 µL Lipofectamine 2,000 into TZMbl
cells was performed in a six-well plate for 2 days. The cells
were trypsinized and re-suspended in 0.2–1.4 mg/mL series of
G418 geneticin (Thermo Fisher Scientific, MA, USA) containing
growthmedium in a 96-well plate, and cultured for at least 7 days,
followed by repeating the selection for a total of three times in the
same manner. The established cells were named TZMbl-10 and
cultured in 0.2–0.4 mg/mL geneticin growth medium.
HIV-1 Infection and Integration
TZMbl and the derived TZMbl-2 and TZMbl-10 cells were
transfected with plasmids, phT2G (16), phT10G, and pUNO1-
hT1 (InvivoGen) expressing TLR10, TLR2, and TLR1, with
PolyJet (SignaGen Rockville, MD, USA) in a 96-well plate for
24 h. The cells were infected with HIV-1 BAL 30-50 TCID50/96-
well plus 12µg/mL DEAE-dextran for 45 h for HIV-1 infection.
The proviral DNA analysis was performed by measuring the
relative light units of luciferase activity for 8 h.
THP-1 cells grown in a 96-well plate were expanded in 8mM
PMA-growth medium for 3 days and PMA-free medium for
another 2 days. The cells were then transfected with specific
siRNAs using Lipofectamine RNAiMAX reagent (Thermo Fisher
Scientific, MA, USA) for 2 days. The cells were infected with
HIV-1 BAL 100 TCID50/well plus 4µg/mL polybrene overnight
and washed with growth medium and cultured for a total of
7 days. HIV-1 integration was detected by the isolation of
total cellular DNA using proteinase K digestion and phenol
extraction, followed by PCR of the viral pol gene. The proviral
DNA was normalized to the cellular 18S rRNA gene in a
same sample.
IL-8 ELISA
IL-8 production from the cell culture was assessed via an
EB ELISA in 20–100-fold dilution as per the manufacturer’s
instruction as described previously (16).
Stimulation of Primary BM Cells in vitro
and Neutralization
Healthy BM was diluted 2-fold in PBS and the cells were isolated
by centrifugation at 800 × g for 20min. The lipid layer and fluid
were removed, and the cell pellet was washed twice with PBS. The
cells were resuspended in a 96-well plate at a density of 1.5× 105
per well with RPMI-1640 medium and cultured overnight.
Since none of the available anti-TLR10 antibodies were able
to efficiently neutralize TLR10 alone under our experimental
conditions (data not shown), we used a cocktail of TLR10
antibodies from different sources comprising rabbit polyclonal
sc-30198 (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
mouse monoclonal sc-293300 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), mouse anti-human TLR10 H00081793-M01
(Novus Biologicals), and mouse monoclonal MA6619 (R&D
Systems) compared to a cocktail control which consisted of rabbit
and mouse isotype IgG controls (Santa Cruz Biotechnology,
Santa Cruz, CA, USA).
Western Blot
The cells were washed with PBS and the lysates were prepared
as previously described (16). Protein quantification was
performed using a DCTM protein assay kit (Bio-Rad) and
run on SDS-PAGE gels. The primary antibodies consisted
of anti-TLR1, anti-TLR2 (R&D Systems), anti-TLR4 (Novus
Biologicals), anti-TLR10 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), phospho-IκBα #9246 (Cell Signaling),
NF-κBα p65 sc-372 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), and anti-β-actin antibodies. HRP-labeled
goat anti-mouse IgG 1706516 (Bio-Rad) and HRP-labeled
goat anti-rabbit IgG 1706515 (Bio-Rad) were used as
secondary antibodies.
Frontiers in Immunology | www.frontiersin.org 12 March 2019 | Volume 10 | Article 482
Henrick et al. TLR10 Significantly Increases HIV-1 Infection
Confocal Microscopy
Immunofluorescence staining was performed as previously
described (54). MCF-10A and THP1 cells grown on an eight-
well BD Falcon culture slides (BD Biosciences) were either left
untreated or treated with Pam3CSK4, or the HIV-1 proteins
p17, p24, and gp41. The cells were fixed and immune-stained
with NF-κBα p65 (1:500) to detect the nuclear translocation
of NF-κBα p65. Corresponding Alexa Fluor 488 conjugated
IgG (Molecular Probes, Eugene, OR, USA) was used as
a secondary antibody. The images were acquired using an
inverted laser-scanning confocal microscope (LSM 510, Zeiss,
Oberkochen, Germany).
Statistical Analysis
The data were plotted and analyzed using Microsoft Excel, SPSS,
and Prism 4.0 software and shown as Mean ± SEM (GraphPad
Software, San Diego, California, USA). Non-parametric tests
were used, including Mann-Whitney U-tests for unmatched
comparisons, Wilcoxon paired t-tests for matched samples, and
a Spearman’s rank test for matched correlations.
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